SPI Infoamtion

Table of Contents

Executive Summary

Overview and epidemiology of CNS disorders
Therapeutic market analysis
Pipeline analysis
Competitive landscape

Scope and methodology

Scope
Methodology

Chapter 1 Overview and epidemiology of CNS disorders

Summary
Introduction

Major depressive disorder (MDD)

Overview
Diagnosis, treatment and management
Epidemiology
Forecast epidemiology

Epilepsy

Overview
Diagnosis, treatment and management
Epidemiology
Forecast epidemiology

Schizophrenia

Overview
Epidemiology
Forecast epidemiology

Alzheimer's disease

Overview
Epidemiology
Forecast epidemiology

Parkinson's disease

Overview
Epidemiology
Forecast epidemiology

Migraine

Overview
Epidemiology
Forecast epidemiology

Insomnia

Overview
Epidemiology

Attention-deficit hyperactivity disorder

Overview
Epidemiology

Chapter 2 Therapeutic market analysis

Summary
Introduction
Key events

Year 2010 to witness launch of multiple anti-Alzheimer's drugs in Japan
Impact of the December 2009 meeting of the FDA Pediatric Advisory
Committee on prescription of antipsychotics

Leading CNS brands
Market analysis by drug class
Performance in the seven major markets
Series of patent expiries to boost generic CNS market through 2014
Drug class analysis

Antipsychotics

Market dynamics
Leading brands
Generic drug trends
Segment forecast to 2014

Antidepressants

Market dynamics
Leading brands
Generic drug trends
Segment forecast to 2014

Anticonvulsants

Market dynamics
Leading brands
Generic drug trends
Segment forecast to 2014

Anti-Alzheimer's drugs

Market dynamics
Leading brands
Generic drug trends
Segment forecast to 2014

ADHD and narcolepsy medications

Market dynamics
Leading brands
Generic drug trends
Segment forecast to 2014

Hypnotic/sedatives

Market dynamics
Leading brands
Generic drug trends
Segment forecast to 2014

Anti-Parkinson's drugs

Market dynamics
Leading brands
Generic drug trends
Segment forecast to 2014

Anti-migraine drugs

Market dynamics
Leading brands
Generic drug trends
Segment forecast to 2014

CNS market forecasts to 2014

Chapter 3 Pipeline analysis

Summary
Introduction
Key trends in R&D

The migraine market is expected to continue its growth over the next few years
Disease modifying therapies hold promise in AD
Novel drugs with differentiated clinical profiles represent a sizeable market opportunity
SSRI generics and branded SNRIs are changing the scenery of the depression market
FDA accepts the extended release NDA for 23mg Aricept
Label expansions of antidepressants provide a significant opportunity for growth
Combination products drive adoption due to better treatment outcomes and improved patient compliance

CNS disorders pipeline

Key products under major CNS disorders

AD
Parkinson's disease (PD)
Depression
Schizophrenia
Epilepsy
Insomnia
ADHD
Other indications

Leading drugs in development
Profiles of key pipeline products

Phase III and pending approval compounds

Bapineuzumab (AAB-001)-Elan/Wyeth/Pfizer
Telcagepant (MK-0974)-Merck
Solanezumab (LY2062430)-Eli Lilly
Semagacestat (LY450139)-Eli Lilly
Vilazodone-Clinical Data

Recently approved/marketed drugs

Stedesa/Zebinix (eslicarbazepine acetate)-Dainippon Sumitomo
(formerly Sepracor)
Saphris (asenapine)-Schering-Plough
Intuniv (guanfacine)-Shire
Treximet (sumatriptan and naproxen)-GSK/Pozen
Pristiq (desvenlafaxine)-Pfizer/Wyeth
Vimpat (lacosamide)-UCB/Schwarz Pharma

Pipeline forecast of key compounds

Chapter 4 Competitive landscape

Summary
Introduction
Detailed analysis of the CNS market players

Johnson & Johnson (J&J)

Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis

Eli Lilly

Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis

GSK

Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis

Pfizer

Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis

AstraZeneca

Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis

Genericization in the CNS market

Chapter 5 Appendix

IMS Data

N2C - Anti-Migraine preparations
N3A - Anti-Epileptics
N4A - Anti-Parkinson drugs
N5A - Antipsychotics
N5B - Hypnotics/Sedatives
N6A - Antidepressants
N6B - Psychostimulants
N7D - Anti-Alzheimer's products
N7X - Other CNS drugs

Leading products by region

United States
Top 5 EU
Japan

Glossary

ADHD-RS
Clinical Dementia Rating (CDR) scale
HAM-D17
Mini Mental State Exam (MMSE)
Neuropsychological Test Battery (NTB)
Personal and Social Performance Scale (PSP)
Positive and Negative Syndrome Scale for schizophrenia (PANSS)

Index

List of Figures
Figure 1.1: Typical treatment patterns in the treatment of schizophrenia
Figure 2.2: Performance of generic products across CNS drug classes, 2008
Figure 2.3: FDA approved indications of leading antipsychotic brands, December 2009
Figure 2.4: Sales pattern of antipsychotics across approved indications in the seven major markets,
2008
Figure 2.5: FDA approved indications of leading antidepressant brands, November 2009
Figure 3.6: Key drugs in late-stage development or that have been recently launched in CNS
disorders
Figure 4.7: Competitive dynamics of the top 10 CNS players over the period 2007-08
Figure 4.8: Drug class focus of J&J, 2008
Figure 4.9: Drug class focus of Eli Lilly, 2008
Figure 4.10: Drug class focus of GSK, 2008
Figure 4.11: Drug class focus of Pfizer, 2008
Figure 4.12: Drug class focus of AstraZeneca, 2008
Figure 4.13: Relative positions of players in the CNS market, 2008
Figure 4.14: Relative positions of generic players in the CNS market, 2008

List of Tables
Table 1.1: Estimated prevalence of CNS disorders across the seven major pharmaceutical
markets, 2008
Table 1.2: Estimated prevalence of MDD across the seven major markets, 2008
Table 1.3: Estimated prevalence of MDD across the seven major markets, 2008-14
Table 1.4: Estimated prevalence of epilepsy across the seven major markets, 2008
Table 1.5: Forecast epidemiology of epilepsy across the seven major markets, 2008-14
Table 1.6: Estimated prevalence of schizophrenia across the seven major markets, 2008
Table 1.7: Forecast epidemiology of schizophrenia across the seven major markets, 2008-14
Table 1.8: Estimated prevalence of AD across the seven major markets, 2008
Table 1.9: Forecast epidemiology of AD across the seven major markets, 2008-14
Table 1.10: Estimated prevalence of PD across the seven major markets, 2008
Table 1.11: Forecast epidemiology of PD across the seven major markets, 2008-14
Table 1.12: Estimated prevalence of migraine across the seven major markets, 2008
Table 1.13: Forecast epidemiology of migraine across the seven major markets, 2008-14
Table 1.14: Estimated prevalence of insomnia across the seven major markets, 2008
Table 1.15: Estimated prevalence of ADHD in adults across the seven major markets, 2008
Table 1.16: Estimated prevalence of ADHD in children across the seven major markets, 2008
Table 2.17: Top 10 CNS products, 2008
Table 2.18: Sales performance of various CNS drug classes, 2008
Table 2.19: Performance of CNS drugs in the seven major markets, 2008
Table 2.20: Global generic drug trends in the CNS market, 2008
Table 2.21: Patent expiries of major CNS brands, 2008-14
Table 2.22: Sales performance of antipsychotic drug classes, 2008
Table 2.23: Formulation profile of leading antipsychotics in the US, November 2009
Table 2.24: Top 10 antipsychotic products, 2008
Table 2.25: Global generic drug trends in the antipsychotics segment, 2008
Table 2.26: Forecast sales of leading antipsychotic brands, 2008-14
Table 2.27: Sales performance of antidepressant drug classes, 2008
Table 2.28: Top 10 antidepressant products, 2008
Table 2.29: Global generic drug trends in the antidepressants segment, 2008
Table 2.30: Forecast sales of leading antidepressant brands, 2008-14
Table 2.31: Sales performance of anticonvulsant drug class, 2008
Table 2.32: Top 10 anticonvulsant products, 2008
Table 2.33: Global generic drug trends in the anticonvulsants segment, 2008
Table 2.34: Forecast sales of leading anticonvulsant brands, 2008-14
Table 2.35: Sales performance of anti-Alzheimer's drug classes, 2008
Table 2.36: Top 10 anti-Alzheimer's products, 2008
Table 2.37: Global generic drug trends in the anti-Alzheimer's drugs segment, 2008
Table 2.38: Forecast sales of leading anti-Alzheimer brands, 2008-14
Table 2.39: Sales performance of drug classes used in treatment of narcolepsy and ADHD, 2008
Table 2.40: Top 10 ADHD and narcolepsy products, 2008
Table 2.41: Global generic drug trends in the ADHD and narcolepsy drugs segment, 2008
Table 2.42: Forecast sales of leading ADHD and narcolepsy brands, 2008-14
Table 2.43: Sales performance of hypnotic/sedative drug classes, 2008
Table 2.44: Top 10 hypnotic/sedative drugs, 2008
Table 2.45: Global generic drug trends in the hypnotic/sedative drugs segment, 2008
Table 2.46: Forecast sales of leading hypnotic/sedative brands, 2008-14
Table 2.47: Sales performance of anti-Parkinson drug class, 2008
Table 2.48: Top 10 anti-Parkinson products, 2008
Table 2.49: Global generic drug trends in the anti-Parkinson drugs segment, 2008
Table 2.50: Forecast sales of leading anti-Parkinson brands, 2008-14
Table 2.51: Sales performance of anti-migraine drug classes, 2008
Table 2.52: Top 10 anti-migraine products, 2008
Table 2.53: Global generic drug trends in the anti-migraine segment, 2008
Table 2.54: Forecast sales of leading anti-migraine brands, 2008-14
Table 2.55: Forecast sales of CNS drug classes, 2008-14
Table 3.56: Global CNS pipeline by indication and stage of development, November 2009
Table 3.57: An overview of bapineuzumab
Table 3.58: An overview of telcagepant
Table 3.59: An overview of solanezumab
Table 3.60: An overview of LY450139
Table 3.61: An overview of vilazodone
Table 3.62: An overview of Stedesa
Table 3.63: An overview of Saphris
Table 3.64: An overview of Intuniv
Table 3.65: An overview of Treximet
Table 3.66: An overview of Pristiq
Table 3.67: An overview of Vimpat
Table 3.68: Key pipeline and recently approved CNS products sales forecast, 2008-14
Table 4.69: Leading players of the CNS market 2008
Table 4.70: Leading brands of J&J, 2008
Table 4.71: J&J's CNS R&D product pipeline, 2009
Table 4.72: Leading brands of Eli Lilly, 2008
Table 4.73: Eli Lilly's CNS R&D product pipeline, 2009
Table 4.74: Leading brands of GSK, 2008
Table 4.75: GSK's CNS R&D product pipeline, 2009
Table 4.76: Leading brands of Pfizer, 2008
Table 4.77: Pfizer's CNS R&D product pipeline, 2009
Table 4.78: Leading brands of AstraZeneca, 2008
Table 4.79: AstraZeneca's CNS R&D product pipeline, 2009
Table 4.80: Patent expirations of key brands of the top five CNS players
Table 5.81: Top 30 CNS products in the US market, 2008
Table 5.82: Top 30 CNS products in the leading 5EU market, 2008
Table 5.83: Top 30 CNS products in the Japanese market, 2008